Regeneron Pharmaceuticals

0:07:06

Regeneron CEO: We want to retain efficacy and eliminate bad side effects with our cancer treatments

0:02:54

What does Regeneron Pharmaceuticals make?

0:02:00

Regeneron CEO On The Eye Drug Market | Forbes

0:06:34

Regeneron Pharmaceuticals CEO: Changing Medicine | Mad Money | CNBC

0:01:09

A Great Place to Work and Live: Our Manufacturing Campuses in the Heart of New York’s Capital Region

0:02:37

Discover Regeneron's Industrial Operations and Product Supply Campus in Raheen

0:04:51

Regeneron’s Mission

0:01:00

Top stock pick: Regeneron Pharmaceuticals #stocks #investing

0:01:29

Life at Regeneron

0:02:14

2023 Year in Review: Our Focus on Genetic Medicines

0:03:29

Regeneron CEO on the prospects for its eye drug Eylea

0:02:08

Biotech company Regeneron launches expansion project

0:05:13

Regeneron, Sanofi Cut Heart Drug's Price to Spur Greater Use

0:08:51

The Rise of Regeneron Pharmaceuticals: Exploring the Company's Success Factors and Stock Valuation

0:00:51

🚨 Regeneron Pharmaceuticals faces a major setback as they lose their defense in a patent lawsuit.

0:05:49

💎Kurshöchststand 💎 bei der Regeneron Pharmaceuticals Aktie - jetzt noch einsteigen ?

0:03:51

2023 Year in Review: Our Progress

0:04:41

Regeneron Pharmaceuticals (REGN) Stock Analysis: Should You Invest?

0:01:07

Winners & Losers: Las Vegas Sands, FMC Corp, Regeneron and Palantir

0:00:57

Meant for More: Unlocking the Future of Genetic Medicines

0:04:29

Why Regeneron's antibody drug will be in short supply

0:04:35

Career Development at Regeneron

0:18:42

Regeneron Pharmaceuticals - Quick Stock analysis

0:11:25

Antikörper-AKTIE vor Durchbruch!? 🤯📈💉 Regeneron Pharmaceuticals Aktie 2021 analysiert (REGN Aktie)